Can Fite Biofarma (XTAE:CANF) Total Tax Payable : ₪0.00 Mil (As of Jun. 2024)

View and export this data going back to 2005. Start your Free Trial

What is Can Fite Biofarma Total Tax Payable?

Can Fite Biofarma's Total Tax Payable for the quarter that ended in Jun. 2024 was ₪0.00 Mil.

Can Fite Biofarma Total Tax Payable Historical Data

The historical data trend for Can Fite Biofarma's Total Tax Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Can Fite Biofarma Total Tax Payable Chart

Can Fite Biofarma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Tax Payable

Get a 7-Day Free Trial

Can Fite Biofarma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Jun24
Total Tax Payable	Get a 7-Day Free Trial															-	-	-	-	-

Can Fite Biofarma Total Tax Payable Calculation

Total Tax Payable is the taxes liability owed to federal, state, and local tax authorities. It is the carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.

Can Fite Biofarma Total Tax Payable Related Terms

Thank you for viewing the detailed overview of Can Fite Biofarma's Total Tax Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Can Fite Biofarma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Can Fite Biofarma Ltd (XTAE:CANF) » Definitions » Total Tax Payable

Comparable Companies

Traded in Other Exchanges

CANF:USA

Address

26 Ben Gurion Street, Ramat Gan, ISR, 5257346

Website

http://www.canfite.com

Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).